ニコチン置換療法の世界市場-2025～2033年

ニコチン置換療法の世界市場は2024年に519億1,000万米ドルに達し、2032年には1,597億米ドルに達すると予測され、予測期間2025年のCAGRは14.4%で成長する見込みです。

ニコチン置換療法（NRT）の世界市場には、ニコチン中毒に伴う禁断症状や欲求を緩和し、ニコチンの投与量をコントロールすることで禁煙を支援するよう設計されたさまざまな製品が含まれます。この医学的に承認されたアプローチは、喫煙者が喫煙に伴う有害な影響を経験することなく、タバコ製品から離れることを支援することを目的としています。

ニコチン置換療法には、ガム、パッチ、トローチ、吸入器、点鼻薬など、さまざまな形態のニコチン送達システムが含まれます。これらの製品により、ユーザーはタバコ依存の解消に取り組みながら、より安全にニコチンを摂取することができます。このような要因が、世界のニコチン置換療法市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

喫煙率の上昇

喫煙率の上昇が世界のニコチン置換療法市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予測されています。

世界の喫煙者数の増加は、ニコチン置換療法（NRT）市場の成長を促進する重要な要因です。健康上の懸念から、禁煙のための効果的な解決策を求める個人が増えるにつれて、ガム、パッチ、吸入器などのNRT製品に対する需要が急増しています。この動向は、喫煙率が依然として高い先進国でも発展途上国でも特に顕著です。

世界保健機関（WHO）によれば、世界的に喫煙率が全般的に低下しているにもかかわらず、約12億5,000万人の成人が依然としてタバコを使用しています。この相当な数は、禁煙を目指す人々にとって不可欠なNRT製品のような禁煙補助薬に対する根強い需要を示しています。喫煙は年間800万人以上の死亡原因となっており、多くの人がタバコの使用に関連する深刻な健康リスクを認識するようになっています。こうした危険性への認識が高まるにつれ、禁煙への意欲が高まり、効果的な禁煙方法への需要が高まっています。

タバコの消費を減らすことを目的とした公衆衛生上の取り組みの一環として、NRT製品の入手可能性は先進国でも発展途上国でも増加しています。政府や保健機関は、これらの製品を、欲求や禁断症状に効果的に対処できる安全な代替品として推進しています。多くの国では、禁煙プログラムの一環としてNRTの使用を奨励する包括的なたばこ規制政策を実施しています。このような取り組みには、禁煙補助剤への資金援助、市民の意識向上キャンペーン、禁煙を目指す個人をよりよくサポートするためのヘルスケア提供者向けトレーニングなどが含まれることが多いです。

例えば、2023年、世界保健機関（WHO）は、効果的な禁煙治療薬への世界のアクセスを改善することを目的とした事前認定手続きを開始しました。このイニシアチブは、禁煙を希望しながらも、特に低・中所得国において、様々な障壁のために必要な治療法へのアクセスができないことが多い、世界の7億5,000万人以上のたばこ使用者のニーズに対応するものであり、特に重要です。

同様に、2024年4月、Kenvueのニコチンガムとニコチンパッチは、WHOの事前承認を受けた最初のニコチン置換療法（NRT）製品となりました。このマイルストーンは、これらの製品の品質と有効性を証明するものであり、禁煙支援を求める人々にとって、より利用しやすいものとなるため、極めて重要です。Kenvueの製品がWHOの事前認定リストに掲載されたことは、禁煙支援を世界的に強化するというコミットメントを意味します。これらすべての要因が、世界のニコチン置換療法市場に需要をもたらしています。

さらに、健康リスクに対する認識向上に対する需要の高まりも、世界のニコチン置換療法市場の拡大に寄与しています。

NRT製品の副作用

ニコチン置換療法（NRT）製品に関連する副作用は、禁煙補助薬の使用を喫煙者に躊躇させる重大な課題です。NRTは欲求や禁断症状を抑えるように設計されていますが、副作用は使用経験や治療へのアドヒアランスに影響を与える可能性があります。NRT製品の一般的な副作用は、頭痛、吐き気、消化器系の問題、めまい、いらいら、睡眠障害などです。

副作用の発生は、NRT製品の使用を思いとどまらせることがあります。不快な症状に遭遇した場合、早々に治療を中止したり、完全に使用を断念したりすることがあります。このような副作用に関する懸念は、NRTは効果がない、または不快であるという認識を助長し、最終的に禁煙を目指す喫煙者の採用率を低下させます。したがって、上記の要因が世界のニコチン置換療法市場の潜在的な成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 喫煙率の上昇
  • 抑制要因
    • NRT製品の副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 製品タイプ別

• ニコチン置換療法
  • 吸入器
  • ガム
  • 経皮パッチ
  • 舌下錠
  • 飴
  • その他
• 電子タバコ
• 加熱式タバコ製品

第7章 投与経路別

• 経皮
• 経口
• 点鼻

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Johnson & Johnson Limited
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Cipla Inc.
• Pfizer Inc.
• Glenmark Pharmaceuticals Limited
• Perrigo Company plc
• Philip Morris Products S.A.
• British American Tobacco plc（BAT）
• Fertin Pharma
• JT International SA.
• Imperial Brands plc

第12章 付録

The global nicotine replacement therapy market reached US$ 51.91 billion in 2024 and is expected to reach US$ 159.70 billion by 2032, growing at a CAGR of 14.4 % during the forecast period 2025-2032.

The global nicotine replacement therapy (NRT) market encompasses a range of products designed to assist individuals in quitting smoking by providing controlled doses of nicotine, thereby alleviating withdrawal symptoms and cravings associated with nicotine addiction. This medically approved approach aims to help smokers transition away from tobacco products without experiencing the harmful effects associated with smoking.

Nicotine replacement therapy includes various forms of nicotine delivery systems, such as gum, patches, lozenges, inhalers, and nasal sprays. These products enable users to obtain nicotine more safely while they work on breaking their tobacco dependence. These factors have driven the global nicotine replacement therapy market expansion.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Smoking

The rising prevalence of smoking is significantly driving the growth of the global nicotine replacement therapy market and is expected to drive throughout the market forecast period.

The increasing number of smokers globally is a significant factor driving the growth of the nicotine replacement therapy (NRT) market. As health concerns prompt more individuals to seek effective solutions for quitting smoking, the demand for NRT products such as gums, patches, and inhalers has surged. This trend is particularly evident in both developed and developing nations where smoking rates remain high.

Despite a general decline in smoking rates worldwide, approximately 1.25 billion adults still use tobacco, according to the World Health Organization (WHO). This substantial number indicates a persistent demand for cessation aids like NRT products, which are essential for those looking to quit. Smoking is responsible for over 8 million deaths annually, with many individuals becoming increasingly aware of the severe health risks linked to tobacco use. As awareness of these dangers grows, more smokers are motivated to quit, driving up the demand for effective cessation methods.

The availability of NRT products is on the rise in both developed and developing countries as part of public health initiatives aimed at reducing tobacco consumption. Governments and health organizations promote these products as safe alternatives to help manage cravings and withdrawal symptoms effectively. Many countries have implemented comprehensive tobacco control policies that encourage the use of NRT as part of smoking cessation programs. These initiatives often include funding for cessation aids, public awareness campaigns, and training for healthcare providers to better support individuals looking to quit.

For instance, in 2023, the World Health Organization (WHO) launched a prequalification procedure aimed at improving global access to effective tobacco cessation medications. This initiative is particularly significant as it addresses the needs of over 750 million tobacco users worldwide who wish to quit but often lack access to necessary treatments due to various barriers, especially in low- and middle-income countries.

Similarly, in April 2024, Kenvue's nicotine gum and patch became the first nicotine replacement therapy (NRT) product to receive WHO prequalification. This milestone is crucial as it validates the quality and effectiveness of these products, making them more accessible to those seeking assistance in quitting tobacco14. The inclusion of Kenvue's products on the WHO prequalification list signifies a commitment to enhancing the support available for tobacco cessation globally. All these factors demand the global nicotine replacement therapy market.

Moreover, the rising demand for increased awareness of health risks contributes to the global nicotine replacement therapy market expansion.

Side Effects of NRT Products

The side effects associated with nicotine replacement therapy (NRT) products present a significant challenge that can deter smokers from using these aids to quit. While NRT is designed to help manage cravings and withdrawal symptoms, the adverse effects can impact user experience and adherence to treatment. Common side effects of NRT products are headaches, nausea, digestive issues, dizziness, irritation, and sleep disturbances.

The occurrence of side effects can discourage some individuals from using NRT products. If users encounter unpleasant symptoms, they may discontinue the therapy prematurely or decide against trying it altogether. Concerns regarding these side effects can foster a perception that NRT is ineffective or uncomfortable, ultimately leading to lower adoption rates among smokers looking to quit. Thus, the above factors could be limiting the global nicotine replacement therapy market's potential growth.

Segment Analysis

The global nicotine replacement therapy market is segmented based on product type, route of administration, distribution channel, and region.

Product Type:

The e-cigarette segment is expected to dominate the global nicotine replacement therapy market share

The e-cigarette segment holds a major portion of the global nicotine replacement therapy market share and is expected to continue to hold a significant portion of the global nicotine replacement therapy market share during the forecast period.

The e-cigarette segment within the global nicotine replacement therapy (NRT) Market has become a prominent component, reflecting evolving consumer preferences and a growing recognition of alternative methods for smoking cessation. This growth is primarily driven by an increasing number of smokers seeking effective alternatives to traditional cigarettes.

E-cigarettes are often regarded as a safer option compared to conventional smoking. Many consumers believe that e-cigarettes pose fewer health risks than combustible tobacco products, which has contributed to their popularity as a smoking cessation tool. The availability of e-cigarettes in numerous flavors, including menthol and fruit options, enhances their appeal, particularly among younger consumers. This flavor diversity not only attracts new users but also assists existing smokers in transitioning away from traditional cigarettes.

Continuous advancements in e-cigarette technology, such as the development of pod systems and advanced vaporization techniques, have improved user experience and satisfaction. These innovations make e-cigarettes more attractive to those looking for alternatives to smoking. The proliferation of vape shops and specialized retail outlets has made e-cigarettes more accessible to consumers. This increased availability supports market growth by providing smokers with convenient purchasing options. Although the e-cigarette market faces regulatory scrutiny, many regions have enacted policies that support their use as smoking cessation aids. This regulatory framework can enhance consumer confidence in using these products to quit smoking.

Furthermore, key players in the industry initiatives and product launches would propel this segment's growth in the nicotine replacement therapies (NRT) market. For instance, in August 2024, Health Canada introduced new measures aimed at preventing potential harm to youth from nicotine replacement therapies (NRT). These initiatives come in response to growing concerns about the recreational use of NRT products among young people, which can lead to nicotine dependence and associated health risks.

Also, in March 2022, Nicorette and NicoDerm unveiled a master brand identity and launched an updated consumer website aimed at better supporting smokers on their journey to quit. This initiative reflects a commitment to enhancing the user experience and providing more personalized resources for those seeking to stop smoking. These factors have solidified the segment's position in the global nicotine replacement therapy market.

Geographical Analysis

North America is expected to hold a significant position in the global nicotine replacement therapy market share

North America holds a substantial position in the global nicotine replacement therapy market and is expected to hold most of the market share.

The North American nicotine replacement therapy (NRT) Market is witnessing substantial growth, driven by several key factors that highlight the increasing demand for effective smoking cessation solutions. Despite ongoing efforts to reduce smoking rates, a significant number of adults in North America continue to smoke. This persistent prevalence creates a strong demand for effective cessation aids, including NRT products such as gums, patches, and inhalers.

Various government programs and policies aimed at reducing smoking rates have been implemented across the region. Growing awareness of the health risks associated with smoking, including chronic diseases such as cardiovascular disease and cancer, has led more individuals to seek help to quit. North America's well-established healthcare infrastructure facilitates access to NRT products. Increased availability through pharmacies, healthcare providers, and online platforms ensures that smokers can easily obtain cessation aids.

The North American market is home to several leading manufacturers of NRT products, such as Pfizer and Johnson & Johnson. These companies are actively engaged in research and development, launching new products and enhancing existing ones to meet consumer needs. Innovations in NRT products have improved their effectiveness and user experience. For instance, advancements in formulations and delivery methods have made products more appealing to consumers, contributing to higher adoption rates.

Furthermore, key players in the industry key initiatives and product launches that would drive this nicotine replacement therapy (NRT) market growth. For instance, in October 2023, in Canada, BC Cancer initiated a Nicotine Replacement Therapy (NRT) pilot program in Prince George, aimed at assisting cancer patients in quitting smoking during their treatment. This program addresses significant barriers that patients, especially those in remote and rural areas, may encounter when trying to access cessation support.

Also, in June 2024, Lupin Limited announced the launch of Varenicline tablets in strengths of 0.5 mg and 1 mg, following approval from the U.S. Food and Drug Administration (USFDA). This product is a generic version of Chantix, a well-known smoking cessation aid originally developed by Pfizer.

Varenicline is indicated as an aid to smoking cessation treatment. It works by targeting nicotine receptors in the brain, which helps reduce cravings and withdrawal symptoms associated with quitting smoking. This mechanism makes it an effective option for individuals looking to overcome nicotine addiction.

Thus, the above factors are consolidating the region's position as a dominant force in the global nicotine replacement therapy market.

Asia Pacific is growing at the fastest pace in the global nicotine replacement therapy market share

Asia Pacific holds the fastest pace in the global nicotine replacement therapy market and is expected to hold most of the market share.

The Asia-Pacific nicotine replacement therapy (NRT) market is poised for significant growth, driven by several key factors that underscore the increasing demand for effective smoking cessation solutions in the region. The Asia-Pacific region has some of the highest smoking rates globally, particularly in countries like China and India. This persistent prevalence creates a substantial demand for effective cessation aids, including NRT products such as gums, patches, and inhalers.

Many governments in the Asia-Pacific region have enacted comprehensive anti-smoking campaigns and policies aimed at reducing tobacco use. This heightened awareness encourages more individuals to seek assistance in quitting, with public health campaigns emphasizing the dangers of tobacco use further motivating smokers to consider NRT options.

Improvements in healthcare infrastructure across the Asia-Pacific region facilitate access to NRT products. Enhanced availability through pharmacies, healthcare providers, and online platforms ensures that smokers can easily obtain cessation aids. Innovations in NRT products have significantly improved their effectiveness and user experience. Advancements in formulations and delivery methods make these products more appealing to consumers, contributing to higher adoption rates.

The Asia-Pacific market features several leading manufacturers of NRT products, such as Japan Tobacco, Cipla, and Rusan Pharma. These companies are actively engaged in research and development, launching new products and enhancing existing ones to meet consumer needs.

Furthermore, key players in the industry key initiatives and product launches that would drive this nicotine replacement therapy (NRT) market growth. For instance, in May 2021, on World No Tobacco Day, JB Chemicals and Pharmaceuticals launched NOSMOK, a line of medicated nicotine lozenges aimed at assisting individuals in their efforts to quit smoking. This initiative is part of a comprehensive 360-degree tobacco cessation program designed to address the challenges faced by smokers seeking to overcome their addiction in Mumbai.

Also, in May 2024, the Department of Health (DH) introduced Chinese medicine ear-point patches as part of a smoking cessation initiative aimed at helping individuals quit smoking. This program is designed to provide smokers with an alternative method for managing cravings and withdrawal symptoms associated with quitting.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global nicotine replacement therapy market.

Competitive Landscape

The major global players in the nicotine replacement therapy market include Johnson & Johnson Limited, Cipla Inc., Pfizer Inc., Glenmark Pharmaceuticals Limited, Perrigo Company plc, Philip Morris Products S.A., British American Tobacco plc (BAT), Fertin Pharma, JT International SA., and Imperial Brands plc among others.

Key Developments

• In June 2024, Ayrton Saunders announced the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approval of its next-generation nicotine inhaler system, designed to provide rapid and safe relief from nicotine cravings to aid smoking cessation. This product, known as the Voke inhaler, is recognized as the world's first clinically approved nicotine replacement therapy (NRT) that delivers nicotine directly through the lungs.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nicotine replacement therapy market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Smoking
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects of NRT Products
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Nicotine Replacement Therapy*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Inhalers
  • 6.2.4. Gum
  • 6.2.5. Transdermal Patches
  • 6.2.6. Sublingual Tablets
  • 6.2.7. Lozenges
  • 6.2.8. Others
• 6.3. E-Cigarettes
• 6.4. Heat-Not-Burn Tobacco Products

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Transdermal*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Oral
• 7.4. Nasal

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Johnson & Johnson Limited*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Cipla Inc.
• 11.3. Pfizer Inc.
• 11.4. Glenmark Pharmaceuticals Limited
• 11.5. Perrigo Company plc
• 11.6. Philip Morris Products S.A.
• 11.7. British American Tobacco plc (BAT)
• 11.8. Fertin Pharma
• 11.9. JT International SA.
• 11.10. Imperial Brands plc

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us